A slower-than-usual year for medtech M&A in 2023 was reflected in relatively few company exits from the Top 100 annual listing of publicly traded device, diagnostics and healthtech companies by re
A slower-than-usual year for medtech M&A in 2023 was reflected in relatively few company exits from the Top 100 annual listing of publicly traded device, diagnostics and healthtech companies by re
The US needs a more diversified pharmaceutical supply chain, but the transition may need to be more delicate than current policy proposals would suggest, FDA Commissioner Robert Califf said. Almost al
US suitability petitions may be seeing renewed interest from sponsors following a surge of filings after the introduction of goal dates in October and then a drop-off of submissions after that. Nimish